Vicarious Surgical Q3 adjusted EPS beats expectations on lower expenses

Vicarious Surgical

12/11/2025 21:29

Overview

Vicarious Surgical Q3 adjusted EPS beats analyst expectations

Operating expenses decreased 35% yr/yr in Q3 2025

Company raised $5.9 mln in direct offering to support operations

Outlook

Company expects full year 2025 cash burn of approximately $50 mln

Result Drivers

COST REDUCTIONS - Operating expenses decreased 35% yr/yr due to reductions in R&D, G&A, and sales and marketing expenses

CAPITAL DISCIPLINE - CEO focuses on reducing burn rate while keeping development timelines on track

FUNDRAISING - Co raised $5.9 mln in direct offering to support operations and goals

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
-$1.91
-$2.33 (3 Analysts)
Q3 EPS
-$1.86
Q3 Adjusted Net Income
Beat
-$11.30 mln
-$14.43 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Vicarious Surgical Inc is $10.00, about 54.3% above its November 11 closing price of $4.57

Press Release: ID:nBwdhV4ka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)